{"id":"NCT01012973","sponsor":"Bayer","briefTitle":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","officialTitle":"A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-02","completion":"2012-02","firstPosted":"2009-11-13","resultsPosted":"2012-11-22","lastUpdate":"2014-11-03"},"enrollment":177,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Retinal Vein Occlusion"],"interventions":[{"type":"BIOLOGICAL","name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"type":"OTHER","name":"Sham treatment","otherNames":[]}],"arms":[{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","type":"EXPERIMENTAL"},{"label":"Sham treatment","type":"SHAM_COMPARATOR"}],"summary":"To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion","primaryOutcome":{"measure":"Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","deltaMin":60.2,"sd":null},{"arm":"Sham Treatment","deltaMin":22.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":73,"countries":["Australia","Austria","France","Germany","Hungary","Italy","Japan","Latvia","Singapore","South Korea"]},"refs":{"pmids":["23298885","24084497"],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":104},"commonTop":["Macular oedema","Nasopharyngitis","Retinal haemorrhage","Intraocular pressure increased","Conjunctival haemorrhage"]}}